Omicia, Inc. Introduces Opal Clinical, Interpretation Software For NGS Diagnostics
OAKLAND, Calif.--(BUSINESS WIRE)--Omicia, Inc., the leading genome interpretation company, today announced the commercial availability of Opal ClinicalTM, the company’s software solution for diagnostic testing organizations. With the cost of next-generation sequencing rapidly decreasing, the time and effort required for interpretation is becoming the rate-limiting factor to making genomics a reality in the clinic. Opal Clinical is a comprehensive solution that addresses this bottleneck. With Opal Clinical, hospitals and diagnostic labs can launch NGS tests faster and interpret results more accurately and quickly.
“We introduce Opal Clinical as genomics expands beyond the research lab into the clinic,” said Mike Aicher, CEO at Omicia. “Opal Clinical meets today’s stringent requirements for clinical bioinformatics solutions -- accuracy, scalability, quick turnaround and repeatability. With Opal Clinical, diagnostic labs have a robust platform to interpret genomic tests and generate clinical reports that help diagnose disease and inform treatment plans. Every step leads us closer to personalized medicine.”
Help employers find you! Check out all the jobs and post your resume.
“We introduce Opal Clinical as genomics expands beyond the research lab into the clinic,” said Mike Aicher, CEO at Omicia. “Opal Clinical meets today’s stringent requirements for clinical bioinformatics solutions -- accuracy, scalability, quick turnaround and repeatability. With Opal Clinical, diagnostic labs have a robust platform to interpret genomic tests and generate clinical reports that help diagnose disease and inform treatment plans. Every step leads us closer to personalized medicine.”
Help employers find you! Check out all the jobs and post your resume.